echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Pl-8177 was designated by FDA as an orphan drug for the treatment of noninfectious uveitis

    Pl-8177 was designated by FDA as an orphan drug for the treatment of noninfectious uveitis

    • Last Update: 2020-06-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    The disease of noninfective uveitis is characterized by swelling or destruction of the eye tissue, which is not caused by active infection, but by inflammation in the eyeAccording to the position of uveitis in the eyes, it can be divided into anterior, middle and posterior uveitisAt first, patients with noninfective uveitis will have symptoms such as blurred vision, eye pain, light sensitivity and dark floating point in visionIf not treated in time, uveitis can lead to vision loss< br / > melanocortin receptor 1 (MC1R) plays an important role in anti-inflammatory response and immune regulationPl-8177, which was designated as orphan drug, is an agonist peptide of selective melanocortin receptor 1 (MC1R), and its structure is a synthetic cyclic heptapeptideThe drug has been evaluated in the animal model of experimental autoimmune uveitis, confirming the efficacy of pl-8177 in reducing inflammation and restoring normal retinal structureAt present, Palatin technologies is studying the oral preparation pl-8177 for the treatment of ulcerative colitis and other inflammatory bowel diseases, as well as the subcutaneous injection preparation for the treatment of noninfectious uveitis< br / > Palatin technologies is designated as an orphan drug by the FDA, which means that the company can not only get help in research and development in clinical development, but also reduce or exempt some FDA fees, and enjoy a seven-year marketing franchise< br / > Palatin technologies revealed that they will submit an ind application for NCM to the FDA in the third quarter of 2019, and plan to conduct the second phase of clinical research in the first half of 2020< br / > note: the original text has been deleted
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.